Eiger Expects To Join Gilead In Future Multi-Billion Dollar Hepatitis D Market
Also Set For COVID-19 EUA
The little-known company could be set for a transformational year, with a Phase III readout in hepatitis D and a filing for a promising COVID-19 candidate.
You may also be interested in...
Public Company Edition: The stock market has been unkind to biotech firms but investors rewarded some drug developers for clinical trial successes, including Scholar Rock and Day One, which raised $205m and $172.5m, respectively. However, some SPAC deals and an IPO never got off the ground.
MYR’s Hepcludex obtained EU accelerated approval in July, making it the first approved therapy for hepatitis D. One analyst sees the drug as a blockbuster revenue opportunity for Gilead.
Many gene therapies companies have faced R&D and financial problems this year but the longer term potential of the field and low prices might tempt big pharma into deals.